IDEXX Laboratories Inc
$
248.54
-1.02 (-0.41%)
| Volume: | 268,134 | Avg Vol (1m): | 476,826 |
| Market Cap $: | 21.38 Bil | Enterprise Value $: | 22.31 Bil |
| P/E (TTM): | 56.12 | P/B: | 421.96 |
| Earnings Power Value | 29.04 |
| Net Current Asset Value | -10.64 |
| Tangible Book | -2.31 |
| Projected FCF | 37.97 |
| Median P/S Value | 107.6 |
| Graham Number | 0 |
| Peter Lynch Value | 82.13 |
| DCF (FCF Based) | 76.03 |
| DCF (Earnings Based) | 88.29 |
YTD (-%)
Add to portfolio
Email alerts
Stock PDF
RSS
Website
Filings
Download Excel
Batch Download
Manual of Stocks™ Web
Manual of Stocks™
Manual of Stocks™ Web
Manual of Stocks™
Financial Strength : 6/10
GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | 0.11 |
Cash-To-Debt ranked
lower than
79.69%
of
261
companies
in the
Diagnostics & Research
industry.
Industry Max: 32990, Med: 3.52, Min: 0.01
IDXX:
0.11
Ranked among companies with meaningful Cash-To-Debt only.
|
Cash-To-Debt range over the past 10 years
Min: 0.11, Med: 10.22, Max: 10000
Current: 0.11
|
| Equity-to-Asset | 0.03 |
Equity-to-Asset ranked
lower than
95.82%
of
239
companies
in the
Diagnostics & Research
industry.
Industry Max: 0.97, Med: 0.61, Min: -2.81
IDXX:
0.03
Ranked among companies with meaningful Equity-to-Asset only.
|
Equity-to-Asset range over the past 10 years
Min: -0.07, Med: 0.77, Max: 0.9
Current: 0.03
|
| Debt-to-Equity | 20.29 |
Debt-to-Equity ranked
lower than
100.00%
of
164
companies
in the
Diagnostics & Research
industry.
Industry Max: 22.86, Med: 0.36, Min: 0.01
IDXX:
20.29
Ranked among companies with meaningful Debt-to-Equity only.
|
Debt-to-Equity range over the past 10 years
Min: -633.99, Med: 0.03, Max: 129.54
Current: 20.29
|
| Debt-to-EBITDA | 1.76 |
Debt-to-EBITDA ranked
lower than
62.93%
of
116
companies
in the
Diagnostics & Research
industry.
Industry Max: 77.72, Med: 1.77, Min: 0.03
IDXX:
1.76
Ranked among companies with meaningful Debt-to-EBITDA only.
|
Debt-to-EBITDA range over the past 10 years
Min: 0.53, Med: 1.53, Max: 3.15
Current: 1.76
|
| Interest Coverage | 15.11 |
Interest Coverage ranked
lower than
66.26%
of
163
companies
in the
Diagnostics & Research
industry.
Industry Max: 15605.52, Med: 76.01, Min: 0.54
IDXX:
15.11
Ranked among companies with meaningful Interest Coverage only.
|
Interest Coverage range over the past 10 years
Min: 10.54, Med: 33.2, Max: 91.84
Current: 15.11
|
| Piotroski F-Score | 8 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 11.31 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | -2.30 |
Not Manipulator
Manipulator
| |
| WACC vs ROIC % |
ROIC 47.97%
WACC 10.89%
| ||
Profitability & Growth : 9/10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | 22.71 |
Operating Margin ranked
higher than
90.50%
of
242
companies
in the
Diagnostics & Research
industry.
Industry Max: 53.36, Med: -0.59, Min: -70300
IDXX:
22.71
Ranked among companies with meaningful Operating Margin only.
|
Operating Margin range over the past 10 years
Min: 17.06, Med: 19.38, Max: 22.71
Current: 22.71
|
| Net Margin % | 17.33 |
Net Margin ranked
higher than
86.31%
of
241
companies
in the
Diagnostics & Research
industry.
Industry Max: 41.13, Med: -2.48, Min: -119600
IDXX:
17.33
Ranked among companies with meaningful Net Margin only.
|
Net Margin range over the past 10 years
Min: 11.85, Med: 13.04, Max: 17.33
Current: 17.33
|
| ROA % | 25.17 |
ROA ranked
higher than
93.13%
of
262
companies
in the
Diagnostics & Research
industry.
Industry Max: 1174.65, Med: -4.54, Min: -1248.4
IDXX:
25.17
Ranked among companies with meaningful ROA only.
|
ROA range over the past 10 years
Min: 13.44, Med: 16.16, Max: 25.17
Current: 25.17
|
| ROC (Joel Greenblatt) % | 86.09 |
ROC (Joel Greenblatt) ranked
higher than
89.96%
of
259
companies
in the
Diagnostics & Research
industry.
Industry Max: 17601.65, Med: -9.57, Min: -3842027.78
IDXX:
86.09
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
|
ROC (Joel Greenblatt) range over the past 10 years
Min: 53.83, Med: 65.41, Max: 92.36
Current: 86.09
|
| 3-Year Total Revenue Growth Rate | 11.40 |
3-Year Revenue Growth Rate ranked
higher than
72.53%
of
182
companies
in the
Diagnostics & Research
industry.
Industry Max: 371, Med: 4.8, Min: -100
IDXX:
13.5
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
|
3-Year Revenue Growth Rate range over the past 10 years
Min: 8.4, Med: 14.1, Max: 35.6
Current: 13.5
|
| 3-Year Total EBITDA Growth Rate | 15.70 |
3-Year EBITDA Growth Rate ranked
higher than
68.54%
of
178
companies
in the
Diagnostics & Research
industry.
Industry Max: 141.7, Med: 10.1, Min: -340.1
IDXX:
18
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
|
3-Year EBITDA Growth Rate range over the past 10 years
Min: -31.5, Med: 15.9, Max: 96.9
Current: 18
|
| 3-Year EPS w/o NRI Growth Rate | 27.60 |
3-Year EPS w/o NRI Growth Rate ranked
higher than
62.58%
of
163
companies
in the
Diagnostics & Research
industry.
Industry Max: 138.7, Med: 10.1, Min: -301
IDXX:
27.6
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
|
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 16, Max: 50.4
Current: 27.6
|
» IDXX's 30-Y Financials
Financials (Next Earnings Date: 2019-08-01)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NAS:IDXX
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Medical Diagnostics & Research » Diagnostics & Research   NAICS : 325412   SIC : 2835 |
| Compare | NYSE:MTD XSWX:LONN NYSE:LH SHSE:603259 NYSE:A NYSE:WAT NYSE:DGX NAS:EXAS NYSE:IQV TSE:6869 XTER:SRT3 NAS:DXCM NYSE:PKI XPAR:BIM NYSE:BIO NYSE:QGEN XPAR:ERF NAS:ICLR NYSE:CRL NAS:PRAH |
| Traded in other countries | IX1.Germany 0J8P.UK |
| Address | One IDEXX Drive, Westbrook, ME, USA, 04092 |
| IDEXX Laboratories Inc primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, laboratory equipment for blood-panel analysis, reference lab services, and tests to detect and manage disease in livestock. Idexx gets about 42% of its revenue from outside the United States. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PE Ratio (TTM) | 56.12 |
PE Ratio ranked
lower than
83.19%
of
113
companies
in the
Diagnostics & Research
industry.
Industry Max: 1345, Med: 35, Min: 0.33
IDXX:
56.12
Ranked among companies with meaningful PE Ratio only.
|
PE Ratio range over the past 10 years
Min: 15.18, Med: 32.37, Max: 73.42
Current: 56.12
|
| Forward PE Ratio | 52.08 |
Forward P/E ranked
lower than
97.50%
of
40
companies
in the
Diagnostics & Research
industry.
Industry Max: 78.74, Med: 9999, Min: 11.64
IDXX:
52.08
Ranked among companies with meaningful Forward P/E only.
| N/A |
| PE Ratio without NRI | 56.12 |
PE without NRI ranked
lower than
83.19%
of
113
companies
in the
Diagnostics & Research
industry.
Industry Max: 1345, Med: 35.56, Min: 0.34
IDXX:
56.12
Ranked among companies with meaningful PE without NRI only.
|
PE without NRI range over the past 10 years
Min: 15.18, Med: 32.37, Max: 73.42
Current: 56.12
|
| Price-to-Owner-Earnings | 73.50 |
Price-to-Owner-Earnings ranked
lower than
75.00%
of
76
companies
in the
Diagnostics & Research
industry.
Industry Max: 1523.53, Med: 36.75, Min: 4.91
IDXX:
73.5
Ranked among companies with meaningful Price-to-Owner-Earnings only.
|
Price-to-Owner-Earnings range over the past 10 years
Min: 21.36, Med: 35.76, Max: 75.79
Current: 73.5
|
| PB Ratio | 421.96 |
PB Ratio ranked
lower than
100.00%
of
245
companies
in the
Diagnostics & Research
industry.
Industry Max: 270, Med: 4.02, Min: 0.15
IDXX:
421.96
Ranked among companies with meaningful PB Ratio only.
|
PB Ratio range over the past 10 years
Min: 3.87, Med: 7.94, Max: 852.86
Current: 421.96
|
| PS Ratio | 9.70 |
PS Ratio ranked
lower than
71.74%
of
230
companies
in the
Diagnostics & Research
industry.
Industry Max: 6350, Med: 3.81, Min: 0.07
IDXX:
9.7
Ranked among companies with meaningful PS Ratio only.
|
PS Ratio range over the past 10 years
Min: 1.75, Med: 4.21, Max: 10.68
Current: 9.7
|
| Price-to-Free-Cash-Flow | 83.74 |
Price-to-Free-Cash-Flow ranked
lower than
76.25%
of
80
companies
in the
Diagnostics & Research
industry.
Industry Max: 1356.19, Med: 29.22, Min: 0.35
IDXX:
83.74
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
|
Price-to-Free-Cash-Flow range over the past 10 years
Min: 13.01, Med: 35.75, Max: 84.69
Current: 83.74
|
| Price-to-Operating-Cash-Flow | 54.84 |
Price-to-Operating-Cash-Flow ranked
lower than
82.47%
of
97
companies
in the
Diagnostics & Research
industry.
Industry Max: 1739.7, Med: 19.94, Min: 0.35
IDXX:
54.84
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
|
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 11.4, Med: 25.52, Max: 58.63
Current: 54.84
|
| EV-to-EBIT | 43.55 |
EV-to-EBIT ranked
lower than
76.27%
of
118
companies
in the
Diagnostics & Research
industry.
Industry Max: 341.21, Med: 25.06, Min: 5.74
IDXX:
43.55
Ranked among companies with meaningful EV-to-EBIT only.
|
EV-to-EBIT range over the past 10 years
Min: 10.5, Med: 22.25, Max: 50.7
Current: 43.55
|
| EV-to-EBITDA | 37.42 |
EV-to-EBITDA ranked
lower than
79.55%
of
132
companies
in the
Diagnostics & Research
industry.
Industry Max: 486.47, Med: 20.75, Min: 3.94
IDXX:
37.42
Ranked among companies with meaningful EV-to-EBITDA only.
|
EV-to-EBITDA range over the past 10 years
Min: 8.2, Med: 18.3, Max: 42.9
Current: 37.42
|
| EV-to-Revenue | 9.91 |
EV-to-Revenue ranked
lower than
69.42%
of
242
companies
in the
Diagnostics & Research
industry.
Industry Max: 19679, Med: 4.24, Min: 0.09
IDXX:
9.91
Ranked among companies with meaningful EV-to-Revenue only.
|
EV-to-Revenue range over the past 10 years
Min: 1.8, Med: 4.3, Max: 11
Current: 9.91
|
| PEG Ratio | 3.13 |
PEG Ratio ranked
lower than
62.50%
of
48
companies
in the
Diagnostics & Research
industry.
Industry Max: 128.13, Med: 3.26, Min: 0.32
IDXX:
3.13
Ranked among companies with meaningful PEG Ratio only.
|
PEG Ratio range over the past 10 years
Min: 0.78, Med: 2.38, Max: 4.68
Current: 3.13
|
| Shiller PE Ratio | 108.86 |
Shiller PE Ratio ranked
lower than
89.74%
of
39
companies
in the
Diagnostics & Research
industry.
Industry Max: 459.08, Med: 52.49, Min: 10.19
IDXX:
108.86
Ranked among companies with meaningful Shiller PE Ratio only.
|
Shiller PE Ratio range over the past 10 years
Min: 26.11, Med: 51.29, Max: 126.39
Current: 108.86
|
| Current Ratio | 1.01 |
Current Ratio ranked
lower than
89.60%
of
250
companies
in the
Diagnostics & Research
industry.
Industry Max: 97.84, Med: 2.58, Min: 0.02
IDXX:
1.01
Ranked among companies with meaningful Current Ratio only.
|
Current Ratio range over the past 10 years
Min: 0.85, Med: 2.89, Max: 8.34
Current: 1.01
|
| Quick Ratio | 0.74 |
Quick Ratio ranked
lower than
89.20%
of
250
companies
in the
Diagnostics & Research
industry.
Industry Max: 97.84, Med: 2.14, Min: 0.02
IDXX:
0.74
Ranked among companies with meaningful Quick Ratio only.
|
Quick Ratio range over the past 10 years
Min: 0.62, Med: 2.03, Max: 7.55
Current: 0.74
|
| Days Inventory | 66.78 |
Days Inventory ranked
higher than
54.41%
of
204
companies
in the
Diagnostics & Research
industry.
Industry Max: 917.88, Med: 79.76, Min: 0.37
IDXX:
66.78
Ranked among companies with meaningful Days Inventory only.
|
Days Inventory range over the past 10 years
Min: 63.41, Med: 81.19, Max: 89.55
Current: 66.78
|
| Days Sales Outstanding | 45.58 |
Days Sales Outstanding ranked
higher than
75.49%
of
204
companies
in the
Diagnostics & Research
industry.
Industry Max: 521.64, Med: 67.51, Min: 1
IDXX:
45.58
Ranked among companies with meaningful Days Sales Outstanding only.
|
Days Sales Outstanding range over the past 10 years
Min: 37.43, Med: 41.47, Max: 45.58
Current: 45.58
|
| Days Payable | 26.08 |
Days Payable ranked
lower than
84.49%
of
187
companies
in the
Diagnostics & Research
industry.
Industry Max: 981.81, Med: 63.34, Min: 1
IDXX:
26.08
Ranked among companies with meaningful Days Payable only.
|
Days Payable range over the past 10 years
Min: 13.82, Med: 23.86, Max: 28.04
Current: 26.08
|
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| 3-Year Share Buyback Rate | 1.40 |
3-Year Share Buyback Rate ranked
higher than
98.89%
of
180
companies
in the
Diagnostics & Research
industry.
Industry Max: 3.4, Med: -7.9, Min: -1732.6
IDXX:
1.4
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
|
3-Year Share Buyback Rate range over the past 10 years
Min: -21.4, Med: 2.2, Max: 6.2
Current: 1.4
|
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Projected-FCF | 6.55 |
Price-to-Intrinsic-Value-Projected-FCF ranked
lower than
76.00%
of
75
companies
in the
Diagnostics & Research
industry.
Industry Max: 449, Med: 2.41, Min: 0.47
IDXX:
6.55
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
|
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 1.49, Med: 2.63, Max: 6.93
Current: 6.55
|
| Price-to-DCF (Earnings Based) | 2.82 |
Price-to-Intrinsic-Value-DCF (Earnings Based) ranked
lower than
70.59%
of
17
companies
in the
Diagnostics & Research
industry.
Industry Max: 6.59, Med: 1.86, Min: 0.72
IDXX:
2.82
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
|
Price-to-Intrinsic-Value-DCF (Earnings Based) range over the past 10 years
Min: 1.06, Med: 2.3, Max: 3.74
Current: 2.82
|
| Price-to-Median-PS-Value | 2.31 |
Price-to-Median-PS-Value ranked
lower than
87.56%
of
193
companies
in the
Diagnostics & Research
industry.
Industry Max: 7.22, Med: 1.01, Min: 0.01
IDXX:
2.31
Ranked among companies with meaningful Price-to-Median-PS-Value only.
|
Price-to-Median-PS-Value range over the past 10 years
Min: 0.42, Med: 0.89, Max: 2.43
Current: 2.31
|
| Price-to-Peter-Lynch-Fair-Value | 3.03 |
Price-to-Peter-Lynch-Fair-Value ranked
lower than
83.33%
of
30
companies
in the
Diagnostics & Research
industry.
Industry Max: 15.31, Med: 2.01, Min: 0.83
IDXX:
3.03
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
|
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 0.82, Med: 2.11, Max: 4.9
Current: 3.03
|
| Earnings Yield (Joel Greenblatt) % | 2.29 |
Earnings Yield (Greenblatt) ranked
higher than
66.04%
of
265
companies
in the
Diagnostics & Research
industry.
Industry Max: 17.42, Med: -0.98, Min: -1428.57
IDXX:
2.29
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
|
Earnings Yield (Greenblatt) range over the past 10 years
Min: 2, Med: 4.5, Max: 9.5
Current: 2.29
|
| Forward Rate of Return (Yacktman) % | 19.51 |
Forward Rate of Return ranked
higher than
77.14%
of
70
companies
in the
Diagnostics & Research
industry.
Industry Max: 7802.99, Med: 8.45, Min: -35.9
IDXX:
19.51
Ranked among companies with meaningful Forward Rate of Return only.
|
Forward Rate of Return range over the past 10 years
Min: 12.9, Med: 16.7, Max: 22.4
Current: 19.51
|
More Statistics
| Revenue (TTM) (Mil) $ | 2,251.64 |
| EPS (TTM) $ | 4.43 |
| Beta | 1.49 |
| Volatility % | 29.12 |
| 52-Week Range $ | 176.11 - 256.22 |
| Shares Outstanding (Mil) | 86.1 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 8 |
| Positive ROA | Y |
| Positive CFROA | Y |
| Higher ROA yoy | Y |
| CFROA > ROA | Y |
| Lower Leverage yoy | N |
| Higher Current Ratio yoy | Y |
| Less Shares Outstanding yoy | Y |
| Higher Gross Margin yoy | Y |
| Higher Asset Turnover yoy | Y |